Two immunotherapy drugs before surgery for melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether giving two immunotherapy drugs (fianlimab and cemiplimab) before surgery helps treat melanoma that has spread to nearby lymph nodes or a small number of other sites. The goal is to shrink tumors and improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and able to understand and sign consent forms
- You have melanoma that can be surgically removed, either at initial diagnosis or after it has come back, with measurable tumors on imaging
- Your melanoma is Stage IIIB-D (spread to lymph nodes) or early Stage IV (spread to 1–3 distant sites like lungs or skin, but not brain, bone, or internal organs)
- You have adequate blood cell counts and liver and kidney function (confirmed by recent blood tests)
- You have not received prior immunotherapy for melanoma and are willing to use effective birth control for at least 6 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial is for people with stage III melanoma that can be surgically removed. It compares one immunotherapy drug to a combination of two, to see which works better before surgery.
Hear when a new Melanoma (Skin) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.